Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumorsS. Champiat, et al.ESMO 2024 Abstract available on the ESMO website – Download the abstract and the poster